Publikationsliste (1992-2019)

​

Significant changes of HCV patient characteristics over time in the era of direct antiviral agent (DAA) therapy – are all HCV subpopulations treated similarly? – Results from the GErman hepatitis C COhort (GECCO). Christensen S, Ingiliz P, Schulze zur Wiesch J, Schewe K, Boesecke C, Hueppe D, Baumgarten A, Lutz T, Schmutz G, Simon KG, Berger F, Busch HW, Mauss S. International Liver Conference (ILC/EASL), Paris, 2018 #THU-358.

 

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance associated substitutions in hepatitis C genotype 3 infection. Von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon KG, Busch HW, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh J, Daeumer M, Luebke N, Timm J, Schulze zur Wiesch J, Sarrazin C, *Christensen S. Aliment Pharmacol Ther; 2018 May;47(9):1288-1295. doi: 10.1111/apt.14592

​

Do resistance associated substitutions (RAS) or Ribavirin (RBV) use influence treatment success of Sofosbuvir (SOF)/Velpatasvir (VEL) in chronic hepatitis C genotype 3 (GT 3) infection? – Results from the GErman hepatitis C COhort (GECCO). Christensen S, Ingiliz P, Mauss S, Hueppe D, Baumgarten A, Schmutz G, Simon KG, Berger F, Busch HW, Daeumer M, Schewe K, Rockstroh JK, Lutz T, Timm J, Von Felden J, Schulze zur Wiesch J. The liver meeting (AASLD) 2017, Washington DC, Abstract # 63

​

Does Sofosbuvir (SOF)/Velpatasvir (VEL) with or without Ribavirin (RBV) change the landscape of therapy in chronic hepatitis C genotype 3 (GT 3) infection? – Results from the GErman hepatitis C COhort (GECCO). Christensen S, Ingiliz P, Schewe K, Rockstroh J,  Hueppe D, Baumgarten A, Lutz T, Schmutz G, Simon KG, Berger F, Busch HW, Schulze zur Wiesch J,  Mauss S. The International Liver Congress (ILC, EASL) 2017, Amsterdam, #SAT 275.

​

Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J. J Med Virol. 2017 Jul 15. doi: 10.1002/jmv.24903. [Epub ahead of print].

​

​​Sofosbuvir and Ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus infection in HCV-monoinfected and HIV-HCV coinfected individuals - Results from the German hepatitis C cohort (GECCO). *Ingiliz P., *Christensen S., Kimhofer T., Hueppe D., Lutz T., Schewe K., Busch H., Schmutz G., Wehmeyer MH., Boesecke C., Simon KG., Berger F., Rockstroh JK., Schulze zur Wiesch J., Baumgarten A., Mauss S. Clin Infect Dis, 2016 Nov 15;63(10):1320-1324. Epub 2016 Aug 17.

​

Sofosbuvir and ledipasvir for 8 weeks in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice - Results from the GErman hepatitis C COhort (GECCO). Christensen S,  Mauss S, Hueppe D, Schewe K, Lutz T, Rockstroh J,  Schuetze M, Schmutz G, Simon KG, Busch HW, Ingiliz P, Baumgarten A. The liver Meeting (AASLD) 2016, San Francisco, USA, #1081.

​

​Relapse and treatment ermergent RAVs with DAA-based regiments in hepatitis C virusinfection (HCV) mono-or-human immunodeficiency virus (HIV)-HCV Co-infected patients – a real concern in clinicalpractice? Results from the German hepatitis C cohort (GECCO). Christensen S, Ingiliz P, Schewe K, Busch HW, et al.J Hepatol 2016; 64 (Suppl 2): SAT-265.

​

Sofosbuvir-based treatments for patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice – Results from the GErman hepatitis C COhort (GECCO). Mauss S, Schewe K, Rockstroh J, Hueppe D, Baumgarten A, Schmutz G, Simon KG, Lutz T, Busch HW, Ingiliz P, Christensen S. The liver Meeting (AASLD) 2015, San Francisco, USA, #1156.

​

Sofosbuvir and ledipasvir for 8 weeks in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice - Results from the GErman hepatitis C COhort (GECCO). Christensen S,  Mauss S, Hueppe D, Schewe K, Lutz T, Rockstroh J,  Schuetze M, Schmutz G, Simon KG, Busch HW, Ingiliz P, Baumgarten A. The liver Meeting (AASLD) 2015, San Francisco, USA, #1081.

​

Effects of HCV therapy with direct acting antiviral agents on lipids in the German multicenter cohort (GECCO). Mauss S, Berger F, Ingiliz P, Hueppe D, Lutz T, Simon KG, Schewe K, Wasmuth C, Busch H, Baumgarten A, Christensen S. 15. European AIDS Conference, Barcelona, Spain 2015, PE13/44.

​

​​​​​German cohort on sofosbuvir based therapy for HCV/HIV- and HCV-infection (GECOSO) S. Christensen, P. Ingiliz, D. Hüppe, T. Lutz, K.-G. Simon, K. Schewe, H. Busch, A. Baumgarten, G. Schmutz, St. Mauss.  The Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, USA, 2015, Poster #646

​

Non-virological factors predicting patient adherence during antiviral treatment of genotype 1/4 infection in real world: role of gender and age. T. Witthoeft, S. Christensen, H.W. Busch, W. Gickler, H. Steffens, C. John, S. Holm, A. von Lucadou, E. Zehnter, H. Cordes,|D. Hueppe, H.W. Blaak, D. Hartmann, M. Bilzer. The 64nd Annual Meeting Of The American Association For The Study Of The Liver (AASLD), Washington, USA, 2013, Abstract # 1902

​

Elevated glucose, metabolic syndrome and diabetes predict lower treatment response to triple therapy with telaprevir in HCV. E. Jaeckel, C. John, R. Heyne, G. Teuber, W. Schiffelholz, S. Christensen, C. Antoni, S. Pape, M. Roessle, H.F. Loehr, K.H. Boeker, A. Schober, H. Bruch, S. Mauss, H. Steffens,|U. Alshuth. The 64nd Annual Meeting Of The American Association For The Study Of The Liver (AASLD), Washington, USA, 2013, Abstract # 1948.

 

Safety and efficacy of triple therapy containing boceprevir (BOC) or telaprevir (TVR) plus peginterferon alfa-2a/ ribavirin in patients with advanced fibrosis or cirrhosis in real-life setting. S. Mauss, A. Schober, C. John, T. Lutz, G. Moog, H. Bruch, G. Teuber, S. Christensen, R. Heyne, S. Pape, U. Naumann, M. Roessle, W. Schiffelholz, H.F. Loehr, U. Alshuth, D. Hueppe. The 64nd Annual Meeting Of The American Association For The Study Of The Liver (AASLD), Washington, USA, 2013, Abstract # 1856.

​

Patient Adherence: the Influence of Non-virological Factors in a Real Word Setting. Thomas Witthoeft, Ralph Link, Stefan Christensen, Heiner W. Busch, Wolfgang Gickler, Hermann Steffens, Christine John, Stefanie Holm, Armand von Lucadou, Elmar Zehnter, Hans-Jörg Cordes, Dietrich Hueppe, Harald W. Blaak, Andreas Heuser, Manfred Bilzer. The 63nd Annual Meeting Of The American Association For The Study Of The Liver (AASLD), Boston, USA, 2012, Abstract # 757

​

Patient Adherence: The Influence of Non-Virological Factors in a real World settingt. Witthöft, R Link, S Christensen, H.W. Busch, W Gickler, H Steffens, C John, S Holm, A von Lucadou, E Zehnter, H-J Cordes, D Hüppe, H Blaak, A Heuser, M Bilzer, DGSV, Hamburg, Germany, 2012, Abstract # A-483-0010-00425

​

Longterm Outcome of Interferon/Ribavirin treatment in German Real-Life setting: Durable SVR associated with low rates of Liver-Related events. Stefan Mauss, Jörg Petersen, Thomas Witthoeft, Heiner W. Busch, Stefan Christensen, Elmar Zehnter, Christine John, Jörg Gölz, Katja Nowak, Manfred Bilzer, Dietrich Hüppe, The 62st Annual Meeting Of The American Association For The Study Of The Liver (AASLD), San Francisco, USA, 2011, Abstract # 1338

​

Longterm benefits of sustained virological response (SVR) in Patients with chronic Hepatitis C (CHC) Virus Infection: The German LOTOS Study. Wedemeyer H., Reimer J., Sandrow P., Hueppe D., Lutz T., Gruengreiff K., Goelz J., Busch H., Christensen S., Hribar I., Alshut U., The Digestive Disease Week 2011 (DDW) in Chicago, USA, 2011, Abstract # 6795

​

Longterm Outcome of Chronic Hepatitis C (CHC) Virus Infection in a real World Setting: The German LOTOS Study. Wedemeyer H., Reimer J., Sandrow P., Hüppe D., Lutz T., Gruengreiff K., Goelz J., Busch H., Christensen S., Hribar I., Alshut U., The 61st Annual Meeting Of The American Association For The Study Of The Liver (AASLD), Boston, USA, 2010, Abstract # 973

​

HIV-Infektion und AIDS-Erkrankung. H. Busch, S. Christensen, C. Weishaupt. Suchtmedizinische Versorgung. Springer-Verlag 2000;143-159. ISBN 3-540-655582-4.

​

D4T ist a reliable drug for the treatment of HIV-infected pregnant woman. C. Weishaupt, S. Christensen, H. Busch; Abstract 0501, 2nd Conference on Global strategies for the prevention of HIV transmission from mothers to infants, 1999, Montreal, Canada.

​

Initiation of a treatment with Zidovudine in combination with Zalcitabine in 95 HIV-infected patients with a previous Zidovudine monotherapy: Experiences of the Ambulance of Acquired Immunodeficiency of the WWU Münster. H. Busch, S. Christensen, D. Reichelt, S. Jahn, W. Zidek
4th European Conference on Clinical Aspects and Treatment of HIV-Infection, P255, Milano 1994

​

Treatment of HIV-infected patients with advanced symptomatic disease with WF10 solution (TCDO). H. Busch, S. Christensen, D. Reichelt, S. Jahn, W. Zidek. X. International Conference on AIDS, PB0245, Yokohama 1994

Zidovudine or Zidovudine/Acyclovir in patients with asymptomatic HIV-infection and CD4-cell counts greater than 400/µl. S. Jahn, H. Busch, D. Reichelt, S. Christensen, W. Zidek.
X. International Conference on AIDS, PB0280, Yokohama 1994

Antiretrovirale Kombinationstherapie-Therapie der HIV-Infektion. H.W. Busch; S. Christensen (Hrsg.) Schriftenreihe des Kuratoriums für interdisziplinäre Medizin, Forschung, Behandlung und Prävention von AIDS und Suchtkrankheiten e.V.. - 1. Auflage - Düsseldorf, Severin & Partner GmbH, 1994

Die Indikation einer polyvalenten intravenösen Immunglobulintherapie im Rahmen der HIV-Erkrankung. HIV-Medizin: Möglichkeiten der individualisierten Therapie; H.W. Busch, S. Christensen, D. Reichelt. Wissenschaftliche Ergebnisse in der Mitte der 90er Jahre/[4. Münchener AIDS-Tage 1994]. H. Jäger (Hrsg.) ecomed, 1994, S. 324-325

Initiation of a treatment with Zidovudine in combination with Zalcitabine in 64 HIV-infected patients with previous Zidovudine monotherapy. S. Christensen, H.W. Busch, U. Hoffmann, D. Reichelt, S. Jahn, W. Zidek. IX. International Conference on AIDS, PO-B26-2103, Berlin 1993

Zidovudine 800 mg or Zidovudine 500 mg in combination with Acyclovir for treatment of HIV-infection. S. Jahn, H.W. Busch, D. Reichelt, A. Gillessen, U. Hoffmann, S. Christensen. IX. International Conference on AIDS, PO-B26-2122, Berlin 1993

Levomethadone Maintenance Treatment in HIV-infected intravenious drug users. T. Poehlke, H.W. Busch, S. Christensen, S. Jahn, W. Zidek. IX. International Conference on AIDS, PO-B26-2102, Berlin 1993

Levomethadone maintenance treatment in HIV-infected intravenious drug users. T. Poehlke, H.W. Busch, S. Christensen, S. Jahn. Second European Symposium on Drug Addiction & AIDS, Siena 1993

AIDS und Opiatabhängigkeit. H.W. Busch, T. Poehlke, S. Jahn, D. Reichelt, S. Christensen, W. Zidek. W.Westfälisches Ärzteblatt 11/92, S. 565 ff.